ESPAC-6

An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature - ESPAC-6

III

interventionell

National

Therapeutic intervention of standard adjuvant chemotherapy comprising oxaliplatin- or gemcitabine-based regimens based on standard clinical criteria, compared to selection using a treatment specific signature and prediction model.

Status: In Vorbereitung

Zeitraum

2022

2025

Zentren

30

Auf Anfrage

Patienten

394

30.03.2022

Klinische Settings

adjuvant

1st line

kurativ

Beteiligte

AIO-Arbeitsgruppen

Sponsor

Ruprecht-Karls-Universität Heidelberg

Förderer

Dietmar Hopp Stiftung

Identifier

AIO-PAK-0121/ass

AIO-PAK-0121/ass

Kontakt

Leitung

Prof. Dr. Dr. med. Markus W. Büchler

Ansprechpartner*in

Prof. Dr. Dr. med. Markus W. Büchler
E-Mail markus_buechler@med.uni-heidelberg.de